European Regulators Back Santhera's Expanded Muscular Dystrophy Treatment for Toddlers
Pratteln, Monday, 27 April 2026.
European regulators recommended expanding Santhera’s muscular dystrophy drug to children aged two and older. Notably, the therapy yields an 80% reduction in vertebral fractures compared to traditional treatments.
A Regulatory Milestone for Early Intervention
On April 27, 2026, Santhera Pharmaceuticals (SIX: SANN) announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion to extend the marketing authorization for AGAMREE (vamorolone) [1]. The CHMP, which convened from April 20 to April 23, 2026, formally recommended the label expansion on April 24, 2026 [2]. Currently authorized in the European Union for patients aged four and older, the new recommendation would allow the treatment of Duchenne muscular dystrophy (DMD) in children as young as two years old [1]. This regulatory step now awaits final confirmation from the European Commission to be officially enacted [1].
Clinical Efficacy and Safety Profile
The CHMP’s endorsement is heavily supported by robust clinical data, most notably the Phase 2b VISION-DMD study, where AGAMREE demonstrated a statistically significant improvement in Time to Stand (TTSTAND) velocity compared to a placebo at the 24-week mark (p = 0.002) [1]. Furthermore, long-term data spanning up to eight years of treatment was presented at the MDA Clinical & Scientific Conference in March 2026 [1][3]. This longitudinal data confirmed that AGAMREE maintains comparable effectiveness to classic corticosteroids such as Prednisone (p = 0.8587) and Deflazacort (p = 0.6544), specifically regarding the time to loss of ambulation in patients [3].
Commercial Expansion and Leadership Transition
This clinical progress aligns with aggressive commercial expansion for Santhera. Beyond the anticipated EU label expansion, the company has secured vital reimbursement milestones across Europe. On February 27, 2026, the Spanish Interministerial Commission on Prices of Medicines proposed including AGAMREE in Spain’s National Health System [3]. Shortly after, on April 22, 2026, the Italian Medicines Agency (AIFA) approved the drug’s reimbursement for DMD patients aged four and older [4]. Globally, AGAMREE is approved in major markets including the US, UK, Switzerland, China, and Canada, with regional rights out-licensed to partners like Catalyst Pharmaceuticals for North America and Nxera Pharma for the Asia-Pacific region [1]. This broad footprint contributed to a striking 98% revenue growth for the drug, reported by Santhera on March 12, 2026 [3].